Juniper Names Alicia Secor President and CEO

Juniper Pharmaceuticals, has appointed veteran healthcare executive Alicia Secor as its president and chief executive officer, effective August 1, 2016. Ms. Secor will also be appointed to Juniper’s board.

“Alicia Secor is a proven leader, with an impressive combination of vision, passion and experience building and managing pharmaceutical businesses,” said Jim Geraghty, chairman of the board, Juniper. “She brings directly relevant experience in leading the development of new products through to regulatory approval and commercialization, which is a critical part of Juniper’s go-forward strategy.”

Ms. Secor’ brings more than 25 years’ of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization and global expansion across several therapeutic areas. She joins Juniper from Zafgen where she served as chief commercial officer and played a key role in advancing the company to a Phase 3 pre-commercialization status.

Previously Ms. Secor served 15 years at Genzyme Corporation in diverse leadership roles, most recently as the global general manager for the metabolic disease business.

Ms. Secor succeeds Frank Condella, who announced his intent to retire as Juniper’s president and chief executive earlier this year.